- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01237249
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd).
This is a national, multicenter, open-label, randomized, comparative study designed to compare, first, the TTP of the two treatment schemes proposed (MPV followed by Rd or MPV alternating with Rd) in newly diagnosed MM patients older than 65 years. This comparison will be performing in terms of both efficacy and safety. Up to 120 patients will be included in each treatment arm and evaluated at scheduled visits in up to 3 study periods: Pre-treatment, Treatment and Follow-up.
Primary outcome measure:
- To evaluate the efficacy in terms of time to progression (TTP) at 18 months of MPV and Rd used as either in a sequential or alternating approach in newly diagnosed MM patients older than 65 years.
- To evaluate the toxicity (safety and tolerability) of the sequential versus the alternating use of MPV and Rd.
Secondary outcome measure:
- To evaluate the response, duration of response, progression free survival (PFS), time to next therapy (TNT) and overall survival (OS) in the two different groups of patients.
- To identify, within the group of patients treated with the alternating scheme, the biological characteristics (including a comprehensive genomic analysis) of those patients resistant to one or the other, and patients refractory to both treatments
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The Pre-treatment period includes Screening visit. After providing written informed consent form to participate in the study, patients will be evaluated for eligibility during a screening period of 14 days (Days -14 to -1). If patients meet all inclusion and exclusion criteria will be randomized at the moment of entry in the trial in a 1:1 allocation to receive either MPV followed by Rd (Treatment Group A) or MPV alternating with Rd (Treatment Group B).
Patients in the Treatment Group A will receive nine cycles of MPV consisting on one 6-weeks cycle of Velcade (Bortezomib) as an intravenous bolus twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32) followed by a 10 day rest period (day 33 to 42), in combination with oral Melphalan, once daily on days 1 to 4 and oral Prednisone, once daily on days 1 to 4, followed by eight 4-weeks cycles of Velcade (Bortezomib) as an intravenous bolus on days 1, 8, 15 and 22 followed by a 6 day rest period (days 23 to 28), in combination with Melphalan and Prednisone per os once daily on days 1 to 4, followed by a 24-day rest period (days 5 to 28). After the nine MPV cycles, patients will receive nine cycles of Rd consisting on 4-weeks cycles, including Revlimid (lenalidomide), once daily on days 1-21 followed by a 7 day rest period (days 22 to 28) plus oral dexamethasone, once weekly on days 1,8,15 and 22, followed by a 6 day rest period (days 23 to 28).
Patients in the Treatment Group B will receive the same schedule of therapy, but the MPV cycles will be alternated with Rd cycles. In this treatment Group B, patients will be again randomized to start receiving either MPV or Rd as first cycle of therapy. Overall, patients will receive an identical number of cycles, nine cycles of MPV and nine of Rd. Patients randomized to Treatment Group A relapsing/progressing or with major toxicities under treatment with MPV will be crossover to receive Rd, but only after study coordinator approval.
During the Treatment Period, patients will be evaluated at day 1 of each cycle. After completion of the Treatment Period, all patients will be evaluated every 2 months thereafter.
Safety will be assessed by the monitoring of adverse events, physical examinations, vital signs measurements, and haematology and clinical chemistry test. Response to treatment will be based on EBMT an IMWG criteria. Response to treatment will be evaluated at day 1 of each induction cycle, and every 2 months during thereafter.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Alcorcón, Spanien
- Fundación Hospital Alcorcón
-
Badalona, Spanien
- Hospital de Badalona Germans Trias i Pujol
-
Barcelona, Spanien
- Hospital del Mar
-
Barcelona, Spanien
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spanien
- Hospital Clínic i Provincial de Barcelona
-
Barcelona, Spanien
- H. Vall d'Hebron, Barcelona
-
Barcelona, Spanien
- ICO - Duran i Reynals, Hospitalet de Llobregat
-
Bilbao, Spanien
- Hospital de Cruces
-
Castellón, Spanien
- Hospital General de Castellon
-
Ciudad Real, Spanien
- Hospital General
-
Cuenca, Spanien
- Hospital Virgen de la Luz
-
Cáceres, Spanien
- Complejo Hospitalario de Caceres
-
Cádiz, Spanien
- Hospital Puerta Del Mar
-
Donostia, Spanien
- Hospital Donostia
-
Gandía, Spanien
- Hospital Francesc Borja
-
Girona, Spanien
- ICO - Josep Trueta
-
Guadalajara, Spanien
- Hospital General de Guadalajara
-
Jerez de la Frontera, Spanien
- H. de Jerez
-
Leon, Spanien
- Complejo Hospitalario León
-
Madrid, Spanien
- Hospital Ramón y Cajal
-
Madrid, Spanien
- Hospital La Paz
-
Madrid, Spanien
- Hospital Clinico San Carlos
-
Madrid, Spanien
- Hospital De Fuenlabrada
-
Madrid, Spanien
- Hospital Infanta Leonor
-
Madrid, Spanien
- Hospital De La Princesa
-
Madrid, Spanien
- Hospital del Tajo
-
Madrid, Spanien
- Hospital Universitario Gregorio Maranon
-
Madrid, Spanien
- Hospital Severo Ochoa
-
Madrid, Spanien
- Hospital Infanta Sofia
-
Madrid, Spanien
- Clínica Puerta de Hierro
-
Madrid, Spanien
- Hospital 12 de Octubre. Madrid
-
Madrid, Spanien
- Hospital de Madrid, S.A.- Norte Hospital General
-
Madrid, Spanien
- MD Anderson
-
Manresa, Spanien
- Althaia
-
Murcia, Spanien
- Hospital Virgen de la Arrixaca
-
Murcia, Spanien
- Hospital General Univeristario Morales Messeguer
-
Málaga, Spanien
- Complejo Hospital Costa Del Sol
-
Málaga, Spanien
- Hospital Nuestra Señora de Valme
-
Navarra, Spanien
- Hospital de la Diputación de Navarra
-
Palma de Gran Canaria, Spanien
- Hospital de Gran Canaria Doctor Negrin
-
Palma de Mallorca, Spanien
- Complejo Asistencial Son Dureta
-
Pamplona, Spanien
- Hospital Virgen del Camino
-
Sabadell, Spanien
- Corporacio Sanitaria Parc Tauli
-
Salamanca, Spanien
- Hospital Clinico De Salamanca
-
Santander, Spanien
- Hoaspital Marqués de Valdecilla
-
Santiago de Compostela, Spanien
- Complejo Hospitalario Universitario de Santiago
-
Segovia, Spanien
- Hospital General de Segovia
-
Sevilla, Spanien
- Complejo Hospitalario regional Virgen del Rocio
-
Tarragona, Spanien
- Hospital Joan XXIII
-
Tenerife, Spanien
- Hospital Universitario de Canarias
-
Toledo, Spanien
- Hospital Virgen de la Salud
-
Toledo, Spanien
- Hospital Nuestra Señora del Prado
-
Valencia, Spanien
- Hospital Arnau de Vilanova
-
Valencia, Spanien
- Hospital Universitario Dr. Peset
-
Valencia, Spanien
- Hospital la Fe
-
Valencia, Spanien
- Hospital Clínico de Valencia.
-
Vitoria, Spanien
- Hospital Txagorritxu
-
Zamora, Spanien
- Hospital Virgen de la Concha
-
Zaragoza, Spanien
- Hospital Clinico Lozano Blesa
-
Zaragoza, Spanien
- Miguel Servet
-
-
Baleares
-
Palma de Mallorca, Baleares, Spanien
- H. Son Llàtzer
-
-
Madrid
-
Alcalá de Henares, Madrid, Spanien
- Hospital Principe de Asturias
-
-
Navarra
-
Pamplona, Navarra, Spanien
- Clinica Universitaria de Navarra
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Written informed consent obtained before starting any study-specific procedure.
- Symptomatic elderly MM newly diagnosed by EBMT criteria older than 65 years.
- Performance status (ECOG) ≤ 2.
Have pre-treatment clinical laboratory values meeting the following criteria within 14 days of randomization:
- platelet count ≥ 75x109/L
- haemoglobin ≥ 8g/dL
- absolute neutrophil count (ANC) ≥ 1.0x109/L
- Serum bilirubin ≤ 1.5 mg/dL and alkaline phosphatise ≤ 2.5 x ULN AST, ALT ≤ 2.5 x ULN
- Serum creatinine ≤2,5 mg/dl
Exclusion Criteria:
- Patient previously received treatment with Velcade or Revlimid.
- Patient previously received treatment for Multiple Myeloma.
- Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrolment.
- Patient has hypersensitivity to bortezomib, boron, mannitol or lenalidomide.
- Patient has received other investigational drugs with 28 days before enrolment.
- Patient had a myocardial infarction within 6 months of enrolment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Patient currently is enrolled in another clinical research study and/or is receiving an investigational agent for any reason.
- Radiation therapy within 30 days before randomization, at least patient has had antialgic radiation. Radiation therapy will be afterwards permitted during the treatment period if it is indicated due to the presence of plasmacytomas
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: MPV followed by Revlimid/Low Dose Dexamethasone (Rd)
Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
|
|
Experimental: Alternating MPV with Revlimid/Low Dose Dexamethasone
Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To evaluate the efficacy in terms of time to progression (TTP) at 18 months of MPV and Rd used as either in a sequential or alternating approach in newly diagnosed MM patients older than 65 years.
Zeitfenster: 18 months
|
18 months
|
To evaluate the toxicity (safety and tolerability) of the sequential versus the alternating use of MPV and Rd,in terms of adverse events presented in both groups of patients
Zeitfenster: 6 months
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To evaluate the response in both groups of patients
Zeitfenster: 1 year
|
1 year
|
To identify, within the group of patients treated with the alternating scheme, the biological characteristics (including a comprehensive genomic analysis) of those patients resistant to one or the other, and patients refractory to both treatments
Zeitfenster: 2 years
|
2 years
|
Duration of response in two groups of patients
Zeitfenster: 2 years
|
2 years
|
Progression free survival (PFS) in two different groups of patients
Zeitfenster: 18 months
|
18 months
|
Time to next therapy (TNT)
Zeitfenster: 2 years
|
2 years
|
Overall survival (OS) in the two different groups of patients
Zeitfenster: 5 years
|
5 years
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Perez JJ, Krzeminski P, Puig N, Mateos MV, Garcia-Sanz R, Herrero AB, Gutierrez NC. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol. 2017 Apr 18;10(1):92. doi: 10.1186/s13045-017-0461-8.
- Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martin-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosinol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San Miguel JF; Grupo Espanol de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatias Malignas (GEM/PETHEMA) Cooperative Study Groups. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016 Jun 23;127(25):3165-74. doi: 10.1182/blood-2016-03-705319. Epub 2016 Apr 26.
- Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, Garcia-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Hämatologische Erkrankungen
- Hämorrhagische Störungen
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Multiples Myelom
- Neubildungen, Plasmazelle
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Entzündungshemmende Mittel
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antiemetika
- Magen-Darm-Mittel
- Glukokortikoide
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Antineoplastische Mittel, hormonell
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Dexamethason
- Lenalidomid
- Prednison
- Melphalan
- Bortezomib
Andere Studien-ID-Nummern
- GEM2010MAS65
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Multiples Myelom
-
University Hospital, CaenLaphalAbgeschlossen
Klinische Studien zur Prednison
-
Tel-Aviv Sourasky Medical CenterUnbekanntKatzenkratzkrankheit | Bartonella-InfektionenIsrael
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... und andere MitarbeiterAktiv, nicht rekrutierendVaskulitis | Granulomatose mit Polyangiitis | Wegener GranulomatoseVereinigte Staaten
-
Rabin Medical CenterUnbekanntGlomeruläre ErkrankungIsrael
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)AbgeschlossenMyasthenia gravisThailand, Kanada, Deutschland, Italien, Niederlande, Brasilien, Vereinigte Staaten, Argentinien, Australien, Chile, Japan, Mexiko, Polen, Portugal, Südafrika, Spanien, Taiwan, Vereinigtes Königreich
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosAbgeschlossenAbstoßung einer Nierentransplantation | Andere Komplikationen der NierentransplantationSpanien
-
Prof. Tony hayek MDAbgeschlossenDiabetes | Atherosklerose | DyslipidämienIsrael
-
National Institute for Tuberculosis and Lung Diseases...SuspendiertInterstitielle Lungenerkrankung | Bösartiger LungentumorPolen
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... und andere MitarbeiterAktiv, nicht rekrutierendGranulomatose mit PolyangiitisVereinigte Staaten, Kanada
-
Groupe Hospitalier Pitie-SalpetriereUnbekanntSystemischer Lupus erythematodesFrankreich